000285357 001__ 285357
000285357 005__ 20260225110619.0
000285357 0247_ $$2doi$$a10.1161/STROKEAHA.125.053727
000285357 0247_ $$2pmid$$apmid:41439314
000285357 0247_ $$2ISSN$$a0039-2499
000285357 0247_ $$2ISSN$$a1524-4628
000285357 037__ $$aDZNE-2026-00223
000285357 041__ $$aEnglish
000285357 082__ $$a610
000285357 1001_ $$00000-0003-1203-7540$$aZhang, Ruiting$$b0
000285357 245__ $$aSimple MRI Lesion Levels Improve Two-Year Prognostic Accuracy Beyond Clinical History in CADASIL.
000285357 260__ $$aNew York, NY$$bAssociation$$c2026
000285357 3367_ $$2DRIVER$$aarticle
000285357 3367_ $$2DataCite$$aOutput Types/Journal article
000285357 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772013343_9598
000285357 3367_ $$2BibTeX$$aARTICLE
000285357 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285357 3367_ $$00$$2EndNote$$aJournal Article
000285357 520__ $$aCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary cerebral small-vessel disease. The CADASIL MRI Inventory Tool summarizes individual MRI findings as simple, type-specific lesion levels. We assessed the predictive value of these levels beyond clinical information.At baseline, CADASIL MRI Inventory Tool levels were assigned for periventricular, deep, and superficial white matter hyperintensities, lacunes, cerebral microbleeds, perivascular spaces in the centrum semiovale and basal ganglia, superficial and deep atrophy, large infarcts, and macrobleeds. Outcomes included stroke, migraine with aura (MA), moderate or severe cognitive impairment, and disability, which were assessed at baseline and during 2-year follow-up. Multivariable logistic regression was performed, with adjustment for age, sex, vascular risk factors, mutation location, and education level.We analyzed 743 patients from France, Germany, and Taiwan (mean age, 53±12; 55% with prior stroke; 35% with MA; 15% with disability; 18% with cognitive impairment). At baseline, higher deep white matter hyperintensities and lacune levels were associated with stroke, whereas cerebral microbleeds and superficial atrophy were inversely associated with MA. Superficial atrophy and periventricular white matter hyperintensities were higher, and superficial white matter hyperintensities were lower, among those with cognitive impairment, whereas deep atrophy and lacunes were linked to disability. Over 2 years (n=547), 11.7% experienced ischemic stroke events, 22.2% MA attacks, 6.5% developed disability, and 6.9% moderate or severe cognitive impairment. After adjustment, lacune levels independently predicted ischemic stroke events (odds ratio, 6.10 [95% CI, 2.09-26.02] for all levels combined). Superficial atrophy and higher superficial white matter hyperintensities predicted a lower risk of MA (odds ratio, 0.29 and 0.21 [95% CI, 0.12-0.68] and [0.06-0.77]). Lacunes and deep atrophy predicted disability, and lacunes with superficial atrophy predicted cognitive impairment.CADASIL MRI Inventory Tool lesion levels are differentially associated with CADASIL manifestations and provide independent 2-year prognostic information beyond clinical covariates. These simple measures may supplement clinical evaluation to improve short-term risk stratification and support patient selection in clinical trials.
000285357 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285357 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285357 650_7 $$2Other$$aNOTCH3 mutation
000285357 650_7 $$2Other$$acerebral atrophy
000285357 650_7 $$2Other$$aischemic stroke
000285357 650_7 $$2Other$$alacune
000285357 650_7 $$2Other$$alongitudinal
000285357 650_7 $$2Other$$amicrobleed
000285357 650_7 $$2Other$$awhite matter hyperintensities
000285357 650_2 $$2MeSH$$aHumans
000285357 650_2 $$2MeSH$$aCADASIL: diagnostic imaging
000285357 650_2 $$2MeSH$$aCADASIL: pathology
000285357 650_2 $$2MeSH$$aMale
000285357 650_2 $$2MeSH$$aFemale
000285357 650_2 $$2MeSH$$aMiddle Aged
000285357 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000285357 650_2 $$2MeSH$$aPrognosis
000285357 650_2 $$2MeSH$$aAdult
000285357 650_2 $$2MeSH$$aAged
000285357 650_2 $$2MeSH$$aWhite Matter: diagnostic imaging
000285357 650_2 $$2MeSH$$aWhite Matter: pathology
000285357 650_2 $$2MeSH$$aStroke
000285357 650_2 $$2MeSH$$aCognitive Dysfunction
000285357 650_2 $$2MeSH$$aAtrophy
000285357 7001_ $$00000-0002-1258-8775$$aChen, Chih-Hao$$b1
000285357 7001_ $$aLambert, Louis$$b2
000285357 7001_ $$0P:(DE-HGF)0$$aCheng, Yu-Wen$$b3
000285357 7001_ $$00000-0002-5403-8288$$aLebenberg, Jessica$$b4
000285357 7001_ $$00000-0002-2866-4330$$aTezenas Du Montcel, Sophie$$b5
000285357 7001_ $$00000-0001-6197-6275$$aHervé, Dominique$$b6
000285357 7001_ $$00000-0001-6096-3595$$aGuey, Stephanie$$b7
000285357 7001_ $$0P:(DE-2719)2000030$$aDichgans, Martin$$b8
000285357 7001_ $$00000-0003-3731-5973$$aTang, Sung-Chun$$b9
000285357 7001_ $$00000-0001-8436-6074$$aChabriat, Hugues$$b10
000285357 773__ $$0PERI:(DE-600)1467823-8$$a10.1161/STROKEAHA.125.053727$$gVol. 57, no. 3, p. 758 - 769$$n3$$p758 - 769$$tStroke$$v57$$x0039-2499$$y2026
000285357 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000030$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000285357 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285357 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2025-01-03$$wger
000285357 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-03
000285357 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-03
000285357 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000285357 980__ $$ajournal
000285357 980__ $$aEDITORS
000285357 980__ $$aVDBINPRINT
000285357 980__ $$aI:(DE-2719)5000022
000285357 980__ $$aUNRESTRICTED